COMP <GO>
SMMT vs MRK // ENTERPRISE SCALE & MARKET CAP
Summit Therapeutics Inc. Common Stock (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: SMMT 3
— MRK 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $16.03 (-1.05%) • MKT CAP: $12.96B
market-cap
$12.96B
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | 3.42% | -5.92 | MRK | /fcf-yield <GO> |
| Operating Margin | -36.30% | 34.30% | -70.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -29.80% | 28.10% | -57.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 1.30% | +9.70 | SMMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 56.9 | -6.14 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.92 | +0.05 | SMMT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 18.4x | +15.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $12.96B | $361.02B | -$348.07B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | MRK REV | SMMT GROSS % | MRK GROSS % | SMMT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$323.6M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$142.2M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | -$76.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
MRK // BETA 0.92